208 related articles for article (PubMed ID: 38429161)
1. Current status and future trends of the global burden of MASLD.
Miao L; Targher G; Byrne CD; Cao YY; Zheng MH
Trends Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38429161
[TBL] [Abstract][Full Text] [Related]
2. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer K; Stauber RE
Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
[TBL] [Abstract][Full Text] [Related]
3. The Global Epidemic of Metabolic Fatty Liver Disease.
Lee ECZ; Anand VV; Razavi AC; Alebna PL; Muthiah MD; Siddiqui MS; Chew NWS; Mehta A
Curr Cardiol Rep; 2024 Apr; 26(4):199-210. PubMed ID: 38376745
[TBL] [Abstract][Full Text] [Related]
4. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
5. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
6. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
7. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
Chen L
World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
Qi X; Li J; Caussy C; Teng GJ; Loomba R
Hepatology; 2024 May; ():. PubMed ID: 38722246
[TBL] [Abstract][Full Text] [Related]
9. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
11. A narrative review about cognitive impairment in metabolic Dysfunction-Associated liver disease (MASLD): Another matter to face through a holistic approach.
Meroni M; Longo M; Paolini E; Dongiovanni P
J Adv Res; 2024 Feb; ():. PubMed ID: 38369241
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.
Ossima AN; Brzustowski A; Paradis V; Van Beers B; Postic C; Laouénan C; Pol S; Castéra L; Gautier JF; Czernichow S; Vallet-Pichard A; Larger E; Serfaty L; Zins M; Valla D; Zaleski ID
Clin Diabetes Endocrinol; 2024 Apr; 10(1):9. PubMed ID: 38659082
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
[TBL] [Abstract][Full Text] [Related]
14. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
16. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
[TBL] [Abstract][Full Text] [Related]
17. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
19. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
20. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
